NICE Cancer Drugs Fund (2011, reformed 2016)
The UK created the Cancer Drugs Fund in 2011 so patients could access cancer drugs NICE had rejected as poor value. It was reformed in 2016 to require evidence collection and tighter entry criteria.
The fund provided temporary access to dozens of drugs while their real-world effectiveness was measured.
It became a standard route for interim funding and still operates alongside NICE's routine approval process.
Enhertu's interim funding flows through the Cancer Drugs Fund, showing how the mechanism continues to bridge the gap between NICE decisions and patient access.
